NEO GENOMICS

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



JAK2 V617F Mutation Analysis - Qualitative

Alternative Name
JAK2 Mutation Analysis

Methodology
Molecular

Test Description
Qualitative detection of the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered separately, concurrently with full exon 12-13 sequencing, with reflex to exon 12-13 sequencing, or as part of the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL. Testing is approved for specimens from the state of New York.

Clinical Significance
The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately 40% of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Mutation analysis helps differentiate reactive conditions from myeloproliferative neoplasms (MPNs).

Specimen Requirements
- **Peripheral Blood:** 5 mL EDTA tube
- **Bone Marrow:** 2 mL EDTA tube

Note: Test is RNA-based, NOT suitable for Freeze & Hold option.

Storage & Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.

CPT Code(s)*
81270

New York Approved
Yes

Level of Service
Global

Turnaround Time
7 days

Medical Necessity Resource

Medical Necessity for NeoTYPE Myeloid Profiles

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

Rev. 051724